Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis

Li, Shenglong; Kang, Yue; Zeng, Yu

doi:10.1016/j.bbcan.2023.189033

Cited by 12 publications

(6 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular components of TME encompass various elements, including tumor cells, tumor-associated fibroblasts, endothelial cells, cytokines, growth factors, extracellular vesicles, Treg cells, CD8+ T cells, and other relevant immune cells 51 , among these components, effector T cells, DC, NK, and M1-type TAMs are recognized as crucial anti-tumor immune cells. TAMs, being the predominant immune cell type within the TME, exhibit functional plasticity and can transition between pro-inflammatory M1 and anti-inflammatory M2 phenotypes 53 . Besides, the type of cytokines produced within TME plays a critical role in determining tumor immunotherapy outcome, for their capability of influencing T cell infiltration and macrophage polarization.…”

Section: Discussionmentioning

confidence: 99%

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis

Zou,

Shen,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Ovarian cancer has the highest mortality among gynecological malignancies, and exploring effective strategies to reverse the immunosuppressive tumor microenvironment in patients remains a pressing scientific challenge. In this study, we identified a pyroptosis-related protective factor, GBP5, which significantly inhibits the growth of ovarian cancer cells and patient-derived ovarian cancer organoids, impeding the invasion and migration of ovarian cancer cells. Results of immunohistochemistry and external single-cell data verification were consistent. Further research confirmed that GBP5 in ovarian cancer cell can induce canonical pyroptosis through JAK2/STAT1 pathway, thereby restraining the progression of ovarian cancer. Interestingly, in this study, we also discovered that ovarian cancer cells with high GBP5 expression exhibit increased expressions of CXCL9/10/11 in a co-culture assay. Subsequent immune cell infiltration analyses revealed the remodeling of immunosuppressive microenvironment in ovarian cancer patients, characterized by increased infiltration and polarization of M1 macrophages. External immunotherapy database analysis showed profound potential for the application of GBP5 in immunotherapy strategies for ovarian cancer. Overall, our study demonstrates that the protective factor GBP5 significantly inhibits ovarian cancer progression, triggering canonical pyroptosis through the JAK2-STAT1 pathway. Driven by its pro-inflammatory nature, it can also enhance M1 macrophages polarization and reverse immunosuppressive microenvironment, thus providing new insights for ovarian cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis

Zou,

Shen,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Immunotherapies directed against CAFs within the TME or BME hold crucial potential in the treatment of metastatic CRPC patients. 192 Several chemotherapy formulations delivered through nanocarrier systems have progressed through various stages of clinical trials, with some reaching Phase III and nearing approval. These formulations encompass a range of nanoparticles, including albumin-bound paclitaxel nanoparticles, pathogenic nanoparticle-based gene delivery systems, micelle nanoparticles, and liposome nanoparticles.…”

Section: Clinical Application and Prospects Of Nano-drug Delivery Sys...mentioning

confidence: 99%

Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer

Wang,

Xue,

Yuan

et al. 2024

IJN

View full text Add to dashboard Cite

Currently, pancreatic cancer (PC) is one of the most lethal malignant tumors. PC is typically diagnosed at a late stage, exhibits a poor response to conventional treatment, and has a bleak prognosis. Unfortunately, PC's survival rate has not significantly improved since the 1960s. Cancer-associated fibroblasts (CAFs) are a key component of the pancreatic tumor microenvironment (TME). They play a vital role in maintaining the extracellular matrix and facilitating the intricate communication between cancer cells and infiltrated immune cells. Exploring therapeutic approaches targeting CAFs may reverse the current landscape of PC therapy. In recent years, nano-drug delivery systems have evolved rapidly and have been able to accurately target and precisely release drugs with little or no toxicity to the whole body. In this review, we will comprehensively discuss the origin, heterogeneity, potential targets, and recent advances in the nano-drug delivery system of CAFs in PC. We will also propose a novel integrated treatment regimen that utilizes a nano-drug delivery system to target CAFs in PC, combined with radiotherapy and immunotherapy. Additionally, we will address the challenges that this regimen currently faces.

show abstract

“…Owing to the genetic complexity and heterogeneity of OS, the process of chemoresistance is an intricate biological process involving several molecular interactions. Cancer cells can become resistant to chemotherapy drugs through various mechanisms: (1) impaired DNA repair; (2) reduced drug transport and increased drug efflux; (3) cell apoptosis, invasion, migration, and cycle; (4) autophagy; (5) signaling pathway activation; (6) tumor microenvironment (TME) and angiogenesis (Hueso et al, 2021;Li et al, 2024;Zhu & Li, 2023). The absence of powerful diagnostic markers or therapeutic targets severely limits the prognosis of OS patients.…”

Section: Introductionmentioning

confidence: 99%

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Chen,

Gong,

Zhou

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary malignant bone tumor and is prevalent in children, adolescents, and elderly individuals. It has the characteristics of high invasion and metastasis. Neoadjuvant chemotherapy combined with surgical resection is the most commonly used treatment for OS. However, the efficacy of OS is considerably diminished by chemotherapy resistance. In recent years, noncoding RNAs (ncRNAs), including microRNAs, long noncoding RNAs, and circular RNAs, are hot topics in the field of chemotherapy resistance research. Several studies have demonstrated that ncRNAs are substantially associated with chemoresistance in OS. Thus, the present study overviews the abnormally expressed ncRNAs in OS and the molecular mechanisms involved in chemoresistance, with an emphasis on their function in promoting or inhibiting chemoresistance. ncRNAs are expected to become potential therapeutic targets for overcoming drug resistance and predictive biomarkers in OS, which are of great significance for enhancing the therapeutic effect and improving the prognosis.

show abstract

Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis

Cited by 12 publications

References 145 publications

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis

Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Contact Info

Product

Resources

About